Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers
Chris Bryant(Wellcome Sanger Institute), Andrew J. Massey(Clatterbridge Cancer Centre NHS Foundation Trust)
Cited by 110
Related Papers
Inhibition of the checkpoint kinase Chk1 induces DNA damage and cell death in human Leukemia and Lymphoma cells
|Molecular Cancer|2014|53
Multiparametric Cell Cycle Analysis Using the Operetta High-Content Imager and Harmony Software with PhenoLOGIC
|PLoS ONE|2015|46
Identification of novel,<i>in vivo</i>active Chk1 inhibitors utilizing structure guided drug design
|Oncotarget|2015|44
γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments
|BMC Cancer|2014|33
mTORC1 and DNA‐PKcs as novel molecular determinants of sensitivity to Chk1 inhibition
|Molecular Oncology|2015|24